"Most believe our health system works—until they rely on it." 🏛️🌲

This Sat, Stephanie Santos of the Infusion Access Foundation testifies to ensure chronic disease patients are centered in Oregon's health reform. 🗣️💪

#OregonHealth #InfusionAccessFoundation

This #PIAwarenessMonth, we’re highlighting the "hidden job" of being sick. Meg faced a $6,000 bill after her insurer pocketed her copay assistance without counting it toward her deductible. 💸🚫

Watch her story of resilience & advocacy. #PIAwarenessMonth #iafchampion

America’s medicine cabinet runs through Beijing  China's growing dominance in the pharmaceutical sector poses a threat to US drug innovation and national security. Read about the risks and solutions.

@RepNateMoran outlines the importance of U.S. drug innovation. Ensuring that innovation translates into real impact for patients also means prioritizing access, affordability, and reliable delivery of infusion therapies. zurl.co/hpyXh

Patients who rely on plasma-derived medicines have a powerful perspective, and we want to hear from you. Take the “Global Survey on Plasma-Derived Medicines and Donation” to have your voice heard: zurl.co/jnLsC

Today is #AdrenalDiseaseAwarenessDay! 🏛️✨

Caitlin, a nurse living with adrenoleukocytosis, co-founded an infusion center after feeling like a "number in a chair." Her mission? Reminding patients they have a right to choose where they receive care.

Watch her story!

Patient Experience Survey: UPMC Health Plan Changes – Infusion Therapies Effective January 1, 2026, UPMC Health Plan implemented significant policy changes impacting patients in Pennsylvania. These changes materially affect patients receiving infusion and injectable therapies for chronic inflammatory conditions and create new administrative and financial barriers to care. If you are enrolled in UPMC Health Plan and have been affected by the below changes, we would like to hear from you. Changes to Your Prescription Coverage UPMC Health Plan is changing which medications it covers starting in 2026. These changes affect some treatments for Crohn’s disease and ulcerative colitis. Some medications may no longer be covered or may be harder to get approved, including Tremfya and Omvhoh. To get certain medications approved, UPMC may now require: - Trying other covered medications first - Extra approval steps from your doctor - Limits on how much medication you can receive For medications that are not covered, UPMC may require you to pay entirely out of pocket or impose additional step therapy requirements by requiring proof that you have tried many other treatments (sometimes up to nine). Each treatment may need to be used for about three months before moving on to the next one. Copay Assistance Program Changes UPMC also uses a copay maximizer that enrolls patients in drug manufacturer copay assistance. Here’s what that means for you: - The copay assistance does not count toward your deductible or out-of-pocket maximum. - The plan is able to maximize the value paid by assistance programs while delaying when UPMC Health Plan begins paying its share of drug costs. - You may experience high out-of-pocket costs later in the year, once copay assistance is exhausted. What This Means for You These changes may: - Limit which medications you can access - Delay starting or continuing certain treatments - Increase your out-of-pocket costs later in the year We value your feedback. Completing this survey will help patient advocacy organizations understand the real-world impact of these changes and advocate for improvements. Your responses will remain confidential.

Do you have health insurance through UPMC in Pennsylvania? We want to hear from you! Take a few minutes to tell us about your experience here: zurl.co/3OlsM

A new wave of drug pricing reforms could reshape how patients access medications. Join the @ChronicCarePAon April 9 at 9:30 AM PT/12:30 PM ET to understand what it means. Register: zurl.co/n0uiB

Doctors are taught to look for horses, not zebras. 🦓 After years of recurring infections, Ambrosia self-referred to find her answer: Primary Immunodeficiency.

Watch her story of self-advocacy for #PIAwarenessMonth. 🏛️✨

#ZebraStrong #InfusionAccessFoundation

Today is IgG4-Related Disease (IgG4-RD) Awareness Day, and we are shining a massive spotlight on 2026 Infusion Access Foundation Champion, Mahsa Pazokifard!

🔗 Learn more about Mahsa’s mission: zurl.co/U0il3

#IgG4RD #IgG4RDAwareness #IAFChampions

Finding a center that fits your life shouldn’t be a struggle. Our Infusion Center Locator helps you find verified care options right in your neighborhood.

Exercise your right to choose! Start your search here: zurl.co/hHspT

#InfusionAccess #PatientChoice #ChronicIllness

Big advocacy win in Virginia! Governor Spanberger just signed into law major PBM reforms that include “de-linking” and “rebate pass-through” provisions to help lower costs for patients statewide. Thank you @SpanbergerForVA!

Check out the state-level trends (including in TX) that are raising questions about if/how patients benefit from the #340B program. zurl.co/AzXQv

Amid discussions on healthcare costs and access, policymakers are exploring changes that could impact the ACA marketplace. Stay informed about the evolving landscape of healthcare policy. #HealthcarePolicy #AffordableCareAct

Get the full details here 👉 zurl.co/bJIRf

.@AIDSadvocacy just released comprehensive state-by-state analysis of CAAPs in 2026 marketplace plans. Despite laws in 26 states and a federal court ruling, nearly 40% of plans nationwide still use these harmful policies. Get the data: zurl.co/K9y3u #AllCopaysCount

NEW @AIDSadvocacy report finds nearly 40% of marketplace plans use copay accumulator policies that hurt patients with chronic illnesses. 31 states have plans with CAAPs despite federal court ruling. Download state-by-state data: zurl.co/XJfc6 #AllCopaysCount

The CMS roundtable events will be held April 6 – April 17, 2026, and registration to participate will be open from now until March 6, 2026.


Sign up here: zurl.co/0l3r8

Legislative win in New Mexico! SB 20, signed into law on 3/6, ensures that prior authorizations approved for chronic maintenance medications remain active for three years. This is a huge step toward reducing barriers and ensuring continuity of infusion care. Thank you @GovMLG!

The Wall Street Chameleon: Big Insurance at an Inflection Point | EP 1 In Episode 1 of the HEALTH CARE un-covered Show, we examine what may be an inflection point in the health insurance reform debate. Plus, we're joined by pollster Madeline Conway of Impact Research.

Watch episode 1: #HealthInsurance companies are now Wall Street-controlled conglomerates that have embedded themselves in nearly every corner of American #healthcare. zurl.co/clT7U

"We deserve a strong, sustainable 340B program, focused on patient care.” Ryan Carpenter of the Community Access National Network explains why transparency and accountability must be central to Washington State’s 340B program.

Read more:
zurl.co/TjeAa

2025: Big Insurance’s $1.7 Trillion Year America’s big seven health insurers raked in $54 billion in profits in 2025 — as they covered fewer people, raised prices and steered patients into their own subsidiaries and taxpayer-funded programs.

America’s big 7 health insurers raked in $54 billion in profits in 2025 – as they covered fewer people, raised prices and steered patients into their own subsidiaries and taxpayer-funded programs.” zurl.co/fKkUK

40% of 2026 plans pocket copay assistance without counting it toward your deductible. This "double-dipping" leaves rare disease patients holding the bill. 💸
Pass the #HELPCopaysAct! 🏛️

Full Report via @AIDSAdvocacy: zurl.co/zkqxD

Blog | Infusion Access Foundation

Our latest policy newsletter dives deep into the launch of TrumpRx, the new federal platform designed to bring international "Most Favored Nation" pricing directly to American patients.

zurl.co/wnlbm

Grateful to @SenJohnBarrasso for introducing the Senate Resolution declaring February 28 as Rare Disease Day. This recognition helps shine a light on millions of people affected by rare diseases and the urgent need for research, access, and support. Thank you for your leadership!

Patients clearly need lower drug prices, but government #pricecontrols on medicines, such as #MostFavoredNation proposed by @WhiteHouse, is the wrong strategy. Congress must not codify the #MFN framework.

Points from #SOTU: #HealthInsurance companies should be accountable for their role in the US drug market. Congress must work on #InsuranceReform, as well as reining in #PBMs to lower drug costs.

A #MostFavoredNation policy will weaken biopharma innovation in the U.S. @WhiteHouse, to remain a global leader in lifesaving treatments we must continue to prioritize innovation. Policies like #MFN are not the right path forward. #SOTU

Even though @POTUS has noted the steps needed to rein in #PBMs, Congress must maintain the pressure on #HealthInsurance companies to ensure treatments are more affordable. #SOTU

As @FTC and @USDOL build on Congress’ work to rein in #PBMs and the insurance companies that own them, in light of upcoming #SOTU, Washington must keep the pressure on these vertically integrated companies to lower costs for patients.

Chair Cassidy Continues Investigation into 340B Drug Program, Seeks Information from 340B Prime Vendor | The U.S. Senate Committee on Health, Education, Labor & Pensions WASHINGTON – U.S. Senator Bill Cassidy, M.D. (R-LA), chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, is seeking...

Thank you @SenBillCassidy for advocating for #340B program reform. Learn more about his inquiry into how 340B prime vendor Apexus generates revenue from the program here: zurl.co/upQK3 & check out the @NYTimes investigative piece on Apexus here: zurl.co/4uC6a

Advocacy Win! Colorado lawmakers voted NO on HB26-1056, a bill that could have allowed unregulated third-party vendors to interfere with patient access to infusion and injection medications.

Our Colorado advocates sent 250+ letters. Thank you for your support!